Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have received a consensus rating of “Buy” from the thirty-three research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation, seventeen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $87.04.
Several brokerages recently issued reports on GILD. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price objective on the stock. in a report on Monday, January 29th. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and cut their price objective for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Bank of America lifted their price objective on shares of Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday, February 7th. Finally, BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a report on Thursday, February 8th.
Gilead Sciences (GILD) traded up $0.50 during trading on Tuesday, hitting $79.90. 2,360,000 shares of the stock traded hands, compared to its average volume of 9,940,000. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a market capitalization of $104,350.00, a P/E ratio of 10.40, a PEG ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the previous year, the firm posted $2.70 earnings per share. The company’s revenue was down 18.7% on a year-over-year basis. research analysts expect that Gilead Sciences will post 6.24 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 2.85%. The ex-dividend date is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is currently 27.08%.
In other news, EVP Gregg H. Alton sold 14,435 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $81.54, for a total value of $1,177,029.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 432,768 shares of company stock valued at $33,919,138. 1.30% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock worth $38,836,000 after buying an additional 100,741 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Northern Trust Corp lifted its holdings in Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares in the last quarter. Finally, Toronto Dominion Bank lifted its holdings in Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after buying an additional 75,364 shares in the last quarter. 75.71% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set Gilead Sciences, Inc. (GILD) PT at $87.17” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/23/brokerages-set-gilead-sciences-inc-gild-pt-at-87-17.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.